Advanced search
Publication Cover
Expert Review of Hematology Volume 16, 2023 - Issue 12
Submit an article Journal homepage
650
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Evaluating the effect of immune checkpoint inhibitors on venous thromboembolism in non-small cell lung cancer patients

Xin Hea Department of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, P.R. ChinaView further author information
,
Shan-Na Weib Department of Pulmonary and Critical Care Medicine, Hebei PetroChina Center Hospital, Langfang, P.R. ChinaView further author information
,
Wen-Wen Qina Department of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, P.R. ChinaView further author information
,
Nan Genga Department of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, P.R. ChinaView further author information
,
Bin Lia Department of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, P.R. ChinaView further author information
,
Shan Songa Department of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, P.R. ChinaView further author information
&
Ping Wanga Department of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, P.R. ChinaCorrespondence[email protected]
View further author information
 show all
Pages 1135-1142 | Received 09 Apr 2023, Accepted 18 Oct 2023, Published online: 27 Oct 2023

Figures & data

Figure 1. Flowchart of the study.

Figure 1. Flowchart of the study.

Table 1. The clinical characteristics of patients with NSCLC.

Figure 2. The risk factors for VTE in patients with NSCLC. X- axis represents the odds ratio (OR).Y-axis represents the risk factors.

Figure 2. The risk factors for VTE in patients with NSCLC. X- axis represents the odds ratio (OR).Y-axis represents the risk factors.

Table 2. The risk factors of VTE in patients with NSCLC.

Figure 3. The timing of VTE during diagnosis and treatment in patients with NSCLC. X axis represents the occurrent time of VTE during diagnosis and treatment; Y-axis represents the number of NSCLC patients with VTE.

Figure 3. The timing of VTE during diagnosis and treatment in patients with NSCLC. X axis represents the occurrent time of VTE during diagnosis and treatment; Y-axis represents the number of NSCLC patients with VTE.

Figure 4. The analyze of overall survival for NSCLC patients between VTE group and non-VTE group. X axis represents the occurrent time of VTE; Y-axis represents the survival rate.

Figure 4. The analyze of overall survival for NSCLC patients between VTE group and non-VTE group. X axis represents the occurrent time of VTE; Y-axis represents the survival rate.

Table 3. The analysis of the number of cases of survival and death in NSCLC patients between VTE group and non- VTE group at 12, 24 and 36 months.

Table 4. The clinical characteristics of NSCLC patients who received ICIs treatment.

Figure 5. The risk factors of VTE in patients with NSCLC who received ICIs treatment. X-axis represents the odds ratio (OR), Y-axis represents the risk factors.

Figure 5. The risk factors of VTE in patients with NSCLC who received ICIs treatment. X-axis represents the odds ratio (OR), Y-axis represents the risk factors.

Table 5. The risk factors of VTE in patients with NSCLC who received ICIs treatment.

Table 6. Correlation analysis between different types of ICI and VTE in NSCLC patients who received ICIs treatment.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.